Samsung releases arthritis drugs to enter the US drug market
-
Last Update: 2017-07-26
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
[industry news of China Pharmaceutical network] Samsung, South Korea, will release a cheap generic drug made by it to imitate the famous rheumatoid arthritis drug REMICADE produced by Johnson & Johnson (JNJ) in the United States on Monday It is reported that REMICADE will become the second generic drug on the market The Samsung drug, which will be marketed to healthcare providers by Merck & Co Inc 's U.S sales team, will cost about 35% less than REMICADE's current price (Samsung launches arthritis drugs into the US drug market photo source: Baidu photo) the US Food and Drug Administration approved the generic drugs in April This will be the first drug launched by Samsung business empire in the world's large drug market, reflecting the company's efforts to break through the field of electronic products and realize diversified operation Samsung bioepis Co., Samsung's new biotech company, aims to build so-called brand bio pharmaceuticals such as REMICADE's generic The drug is made up of living cells and is used to treat complex diseases including cancer or arthritis These "biosimilars" are much cheaper than branded drugs, which typically cost tens of thousands of dollars a year.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
